Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation
Alberto Álvarez‐Larrán(Hospital Clínic de Barcelona), C. Besses(Hospital Del Mar), Martin Grießhammer(Klinik und Poliklinik für Psychosomatische Medizin und Psychotherapie), Paola Guglielmelli(Azienda Ospedaliero-Universitaria Careggi), Francisco Cervantes(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Eduardo Arellano‐Rodrigo(Vall d'Hebron Hospital Universitari), Valentín García‐Gutiérrez(Universidad de Alcalá), Pere Barba(Universitat Autònoma de Barcelona), Ana Kerguelen(Hospital Universitario La Paz), Björn Andréasson(NU Hospital Group), Jessica Samuelsson(Karolinska Institutet), Juan Carlos Hernández‐Boluda(Hospital Clínico Universitario de Valencia), Chiara Paoli(University of Genoa), Mary Frances McMullin(Queen's University Belfast), Carmen Burgaleta(Universidad de Alcalá), Rosa Ayala(Hospital Universitario 12 De Octubre), María Teresa Gómez‐Casares(Universidad de Las Palmas de Gran Canaria), Sonja Zweegman(Vrije Universiteit Amsterdam), C. Harrison(Guy's and St Thomas' NHS Foundation Trust), Beatrice Drexler(University Hospital of Basel), A. M. Vannucchi(Azienda Ospedaliero-Universitaria Careggi), J Schwarz(Institute of Haematology and Blood Transfusion), Arturo Pereira, A. Samah(Guy's and St Thomas' NHS Foundation Trust), Francisca Ferrer‐Marín(Centre for Biomedical Network Research on Rare Diseases)
Cited by 149
Related Papers
Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
|Journal of Clinical Oncology|2012|461